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Background: At a time when the molecular epidemiology of methicillin-resistant Staphylococcus
aureus (MRSA) was changing, we sought to characterize several genotypic markers and glycopeptide
susceptibility features of clinical isolates from patients with bacteraemia.
Methods: One hundred and sixty-eight MRSA bloodstream isolates obtained from three multicentre
clinical trials were microbiologically and genotypically characterized.
Results: All isolates were susceptible to vancomycin (MIC 2 mg/L); 38% belonged to accessory gene
regulator (agr) group I, 52% belonged to group II and 10% belonged to group III. Typing of the staphy-
lococcal cassette chromosome mec (SCCmec) showed that 67% were type II and 33% were type IV. The
agr group II polymorphism was associated with SCCmec II (P<0.001). Fifty-three percent of SCCmec II
and 27% of SCCmec IV isolates had vancomycin MICs  1 mg/L (P50.001). One hundred percent of agr
II strains were predicted to be members of clonal complex 5. SCCmec II was the genetic marker most
predictive of vancomycin MICs of  1 mg/L. SCCmec IV isolates were more likely to have vancomycin
MICs  0.5 mg/L.
Conclusions: Given that SCCmec IV is a marker for a community-based organism for which less prior
vancomycin exposure is predicted, we conclude that prior antibiotic exposure in agr group II organ-
isms may account for their increased vancomycin MICs.
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Introduction
Vancomycin has served as the cornerstone of therapy for
serious methicillin-resistant Staphylococcus aureus (MRSA)
infections for 50 years.
1 Despite the fact that microbiological
resistance to vancomycin in S. aureus remains very rare,
recent years have seen a shift upwards in vancomycin MICs
(i.e. the ‘MIC creep’) within the susceptible range,
2–4 with
consequential effects on vancomycin efﬁcacy in MRSA bacter-
aemia and pneumonia.
5–8 In addition to microbiological
susceptibility phenotype, certain genotypic markers may also
serve as a predictor of vancomycin treatment failure in MRSA
bacteraemia.
5,9 However, the relationship between the MRSA
genotype and glycopeptide susceptibility in vitro has not been
extensively studied. We evaluated a multicentre collection of
168 MRSA bloodstream isolates compiled from three prior
clinical trials to further evaluate the relationship between the
MRSA agr type, spa type, and SCCmec type and vancomycin
susceptibility and to evaluate for MRSA strain differences
between the trials.
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Isolates were obtained as part of three multicentre clinical trials
evaluating MRSA bacteraemia.
10–12 PCR was used to characterize
mec cassettes and to characterize accessory gene regulator (agr)
types as described previously.
13–15 spa X-repeat polymorphisms
were determined by nucleotide sequencing, as described pre-
viously.
15,16 A semi-quantitative delta-haemolysin functional assay
was performed to assess agr function.
17 Vancomycin susceptibility
testing was performed by CLSI microdilution methods and was
evaluated for differences based on agr and SCCmec type (MIC 0.5
versus  1 mg/L).
18 Ordinal data were compared using Kruskal–
Wallis analysis of variance. Categorical data were compared using
x
2 or Fisher’s exact test where appropriate. All statistical procedures
were performed with Systat 11 (Systat Software Inc., Point
Richmond, CA, USA).
Results
One hundred and sixty-eight S. aureus isolates from 168 unique
patients were studied. All isolates were susceptible to vanco-
mycin, with MICs of 0.25 mg/L (n¼1), 0.5 mg/L (n¼92),
1.0 mg/L (n¼68) and 2.0 mg/L (n¼7). The isolates consisted of
64 (38%) agr group I, 86 (52%) group II and 18 (10%) group
III MRSA. One hundred and thirteen (67%) were staphylococcal
cassette chromosome mec (SCCmec) II and 55 (33%) were
SCCmec IV. Of the 164 isolates that were tested by spa typing,
83 (50%) were predictive of clonal complex 5.
The agr group II polymorphism was associated with the pre-
sence of SCCmec II (P,0.001) (Figure 1); 73% (83/113) of
SCCmec II were agr group II. Eighty-seven percent (48/55) of
SCCmec IV were agr group I. All (100%) of the agr group II
isolates were predicted to be of clonal complex 5.
Vancomycin MICs were signiﬁcantly higher among SCCmec
II MRSA (P¼0.001) (Figure 2). Fifty-three percent of SCCmec
II and 27% of SCCmec IV isolates had vancomycin MICs
 1 mg/L. Statistically signiﬁcant differences in vancomycin
MICs were not noted between agr groups or spa types. Among
the isolates showing vancomycin MICs of  1 mg/L, 49% were
agr group II, 42% were agr group I and 33% were agr group III
(P¼0.24). Thirty-nine of the 83 (47%) isolates whose spa
typing predicted clonal complex 5 and 33 of 81 (41%) other
clonal complex types had vancomycin MICs  1 mg/L
(P¼0.661).
The function at the agr locus was signiﬁcantly more reduced
among MRSA with higher MICs within the susceptible range
(Figure 3). Decreased delta-haemolysin production was noted in
86%, 66% and 36% of MRSA with vancomycin MICs of 2, 1
and  0.5 mg/L, respectively (P,0.001).
Analysis of the microbiological and genotypic properties of
MRSA was segregated by the clinical studies from which they
were obtained (Table 1). The earlier two studies enrolling
patients in Phase III/IV protocols from 1998 to 2003 highly
weighted towards persistent MRSA bacteraemia (.5 days) and
inclusive of patients in renal failure showed a different spectrum
of organisms from the randomized Phase III trial enrolling from
2002 to 2005 evaluating daptomycin versus comparator and
exclusive of renal failure patients. When compared with the later
daptomycin S. aureus bacteraemia trial, the earlier trials had
MRSA with a lower percentage of agr group I strains (25%
versus 51%) and SCCmec IV strains (88% versus 46%), and a
signiﬁcantly higher percentage of MRSA with vancomycin
MICs  1 mg/L (77% versus 16%) and agr dysfunction (75%
versus 24%).
Discussion
It is well understood that there is a differential response to the
treatment of infection based on host, pathogen and antimicrobial
selection. While appearing straightforward, antibiotic suscepti-
bility as measured in vitro via the determination of an MIC in a
clinical laboratory may be complicated by phenotypes too subtle
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Figure 1. Relationship between accessory gene regulator (agr) type and
SCCmec type in 163 MRSA bloodstream isolates. agr group I versus II,
P,0.001; agr group I versus III, P,0.001; agr group II versus III,
P¼0.004.
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Figure 2. Relationship between SCCmec type and vancomycin MIC values
in 163 MRSA bloodstream isolates (P¼0.001).
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Figure 3. Relationship between delta-haemolysin production (absent or
present) and vancomycin MIC values for 163 MRSA bloodstream isolates
(P,0.001).
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geneous nature of susceptibility to glycopeptides has resulted in
a recently appreciated discordance between microbiological and
clinical vancomycin resistance among serious S. aureus infec-
tions such as bacteraemia and pneumonia.
19
In addition to vancomycin MIC, agr group II MRSA have
also been linked to vancomycin treatment failure in one study,
5
but not in another.
9 With the understanding that different MRSA
clones with speciﬁc genotypic characteristics may predominate
in speciﬁc epidemiological settings with consequential differ-
ences in antimicrobial selection driving the development of
reduced susceptibility, we sought to determine the relationships
between the MRSA agr type, SCCmec type and vancomycin
susceptibility.
We found that MRSA harbouring SCCmec II were more
likely to have vancomycin MICs of  1 mg/L. SCCmec IV iso-
lates were more likely to have vancomycin MICs  0.5 mg/L.
SCCmec II predominated among agr group II strains and
SCCmec IV among agr group I strains.
We noted a strong association between increased vancomycin
MIC within the susceptible range and agr dysfunction shown by
reduced delta-haemolysin activity. Loss of agr has been associ-
ated with the glycopeptide-intermediate S. aureus phenotype,
17
glycopeptide tolerance
17,19 and prolonged bacteraemia.
9 Since a
vancomycin MIC of 2 mg/L has been associated with prolonged
bacteraemia, this new observation is to be expected, based on
prior data.
Given that SCCmec II has been a marker for a healthcare-
associated organism with consequential vancomycin selection
pressure, these data suggest that the prior ﬁnding of agr group II
being associated with vancomycin treatment failure may reﬂect
the fact that these clones have predominated in settings of ante-
cedent vancomycin selection pressure. Consistent with this
premise is that the agr group II, clonal complex 5 USA 100
MRSA clone includes the ﬁrst US and Japanese VISAs and
vancomycin-resistant S. aureus.
20,21 This inference is strengthened
by the ﬁnding of another single-centre study, where agr group III
MRSA clones predominate, that the agr group III genotype was
associated with vancomycin treatment failure.
9 Thus, differences
in vancomycin response at the genetic level likely reﬂect micro-
biological differences rather than intrinsic differences in antibiotic
susceptibility. However, the reasons for the establishment of
different speciﬁc MRSA clones in different settings or even
different hospitals are unknown and warrant further study.
In addition to spatial differences in MRSA susceptibility, an
evaluation of the microbiological and phenotypic properties of
the 168 bacteraemia isolates as they sort out by the previous
studies from which they were derived shows temporal shifts in
MRSA as well. Collectively, the majority (52%) of MRSA in
this study belonged to clonal complex 5 (agr group II).
However, this genotype was not evenly distributed between the
three studies. In the ﬁrst two studies, where patients were
derived from Phase III/IV linezolid and quinupristin/dalfopristin
protocols and enriched for patients with prolonged bacteraemia
on vancomycin, isolates were heavily weighted towards agr
group II (60%), contain SCCmec II, have vancomycin MICs of
at least 1 mg/L and have reduced agr function. In the third
study, where isolates were more contemporary and excluded
patients with renal dysfunction, MRSA were much more likely
to be agr group I, contain SCCmec IV and have lower vancomy-
cin MICs and preserved agr function. Only 44% of MRSA from
the third study are agr group II. These latter attributes are fea-
tures of MRSA that have generally been seen in community-
onset infections. Nevertheless, the ‘hospital’ and ‘community’
labels associated with speciﬁc MRSA genotypes are certain to
break down over time, likely in a fashion similar to that of S.
aureus with penicillin resistance over the past decades.
The ﬁndings from this multicentre study are in agreement
with the recent single-centre study from Detroit by Chua et al.,
20
showing agr group II MRSA to be associated with hospital-
onset infection, SCCmec II and higher vancomycin MICs, and
showing agr group I strains to be associated with community-
onset infection, SCCmec IV and lower vancomycin MICs. Many
agr group I SCCmec IV MRSA have recently been seen in
healthcare-onset infections.
In summary, these ﬁndings highlight important genotypic and
phenotypic characteristics of MRSA bloodstream isolates as they
relate to one another, with SCCmec II being the strongest
Table 1. Shifting molecular epidemiology of MRSA bacteraemia
Characteristic
Sample from studies 1 and 2
(n¼81)
Sample from study 3
(n¼87) P value
Year MRSA isolated 1998–2003 2002–05
agr group, n (%)
I 20 (25%) 44 (51%) 0.001
II 49 (60%) 38 (44%) 0.029
III 12 (15%) 4 (5%) 0.024
SCCmec II, n (%) 71 (88%) 40 (46%) ,0.001
Vancomycin MIC  1 mg/L, n (%) 62 (77%) 14 (16%) ,0.001
d-lysin 0/1, n (%)
a 61 (75%) 21 (24%) ,0.001
Study 1: Moise-Broder et al., 2002. Study continued through year 2003.
Study 2: Moise et al., 2002.
Study 3: Fowler et al., 2006.
aDelta-lysin scoring system: 0, absent; 1, diminished; 2, comparable to agr wild-type strain RN6607 (see reference 17);
3, increased; and 4, markedly increased.
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875predictor of vancomycin MIC at the upper limit of the suscepti-
bility range. Prior vancomycin exposure in CC5 agr II SCCmec
II organisms may account for their higher vancomycin MICs.
Currently, the molecular epidemiology of MRSA is a moving
target, both geographically and temporally, and therefore, con-
siderable strain heterogeneity may be found among different
clinical studies. Therefore, generalizability of ﬁndings from
clinical trials on MRSA bacteraemia to individual clinical
centres needs to be done with caution.
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